Drug Profile
Research programme: cannabinoid-based neurological disorder therapeutics - Aequus Pharmaceuticals/adMare BioInnovations
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Aequus Pharmaceuticals; The Centre for Drug Research and Development
- Developer adMare BioInnovations; Aequus Pharmaceuticals
- Class Antiparkinsonians; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Huntington's disease; Multiple sclerosis; Parkinson's disease
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Epilepsy in Canada
- 28 Jul 2021 No recent reports of development identified for research development in Huntington's-disease in Canada
- 28 Jul 2021 No recent reports of development identified for research development in Multiple-sclerosis in Canada